Latest Distribution Partnerships News

Turners Automotive Group posted a record $63.2 million normalised NPBT for FY26, beating guidance and declaring a 14% higher dividend as it accelerates branch expansion and ecosystem integration.

AFT Pharmaceuticals surged 22% to NZ$254.7 million revenue in FY26, surpassing profit guidance and securing FDA approval to advance a pivotal injectable iron Phase III trial targeting a $7.4 billion market. The company is poised for further global expansion and product launches in FY27.

Osteopore Limited has completed another incremental drawdown of A$250,000 on the second tranche of its redeemable convertible notes, continuing its steady funding progress under a A$20 million subscription agreement with Advance Opportunities Fund.

Memphasys has secured $1.2 million through a share placement to support the global expansion and manufacturing scale-up of its Felix™ sperm selection system. The company also extended a major convertible note, reinforcing financial flexibility amid growing international contracts.

ReNerve Limited has appointed UG Medical to distribute its NervAlign nerve repair products in Malaysia, tapping into a fast-growing healthcare market backed by government investment.

Control Bionics advances its neural-signal technology across assistive communication, sports, and medical sectors, securing key US reimbursement and distribution agreements while broadening its international footprint.

ReNerve has inked an exclusive three-year deal with Hong Kong’s Swedish Trading Company to distribute its nerve repair products across a vast and dynamic healthcare region.

Australian Vintage Limited has locked in a $128 million refinancing deal extending to 2029 and reported a significant cash flow turnaround in FY26, driven by innovation and strategic acquisitions.

Osteopore has secured Hainan FDA approval to clinically use and sell its custom orthopaedic devices at Shanghai Ruijin Hospital’s Hainan branch, marking a key step towards wider China market access. The company has scheduled its first patient surgery for June 2026.

Smartgroup posted robust 2025 results with record customer growth and accelerated EV leasing, backed by strategic digital investments and a $20 million share buy-back plan following fleet portfolio sales.

James Hardie Industries saw a 25% sales increase in FY26 driven by the AZEK acquisition but reported a 75% net income decline amid acquisition costs and margin pressures. The company expects synergy gains and adjusted EBITDA growth in FY27.

Generation Development Group has completed the migration of $1.8 billion in Xplore Wealth managed discretionary accounts to Evidentia’s Implemented Portfolios on the HUB24 platform, lifting total funds under management beyond $4 billion.